Table 2.
Bleeding characteristics and quality of life after 6 months of follow‐up, by intention‐to‐treat analysis
| Outcomes | Intervention n = 51 | Control n = 44 | P |
|---|---|---|---|
| Bleeding/micturition characteristics | |||
| Total days of spottinga | 4 (2–7) | 7 (3–10) | 0.04 |
| Spotting at the end of the menstruation | 3 (2–5) | 5 (2–8) | 0.13 |
| Intermenstrual spotting | 0 (0–0) | 0 (0–3) | 0.15 |
| Discomfort from spotting (0–10) | 2.0 (0–6.8) | 6.9 (0.4–8.0) | 0.02 |
| Dysmenorrhea (0–10) | 3.0 (0–6.2) | 4.3 (0–7.3) | 0.37 |
| Daily pain during micturition | 2 (4.7%) | 3 (7.9%) | 0.67 |
| Quality of life and sexual function | |||
| SF‐36 physical component summary score | 53.1 (45.4–58.7) | 52.1 (46.6–57.7) | 0.67 |
| SF‐36 mental component summary score | 52.6 (47.0–56.9) | 50.0 (44.5–54.2) | 0.05 |
| EuroQol total score | 0.84 (0.81–1.0) | 0.83 (0.72–1.0) | 0.33 |
| FSFI total score | 13.5 (9.8–21.6) | 15.1 (10.0–21.3) | 0.61 |
Data are reported as n (valid percentage) or as median (IQR). Analyses are by intention to treat.
a
Total days of spotting = the sum of the number of days spotting at the end of the menstruation and the number of days of intermenstrual spotting (postmenstrual spotting).